Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak
{"title":"分期 18F-FDG PET/CT 在预测膀胱癌患者总生存期中的附加值","authors":"Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak","doi":"10.4274/mirt.galenos.2023.65002","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This retrospective study aimed to evaluate the prognostic importance of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging <sup>18</sup>F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.</p><p><strong>Methods: </strong>Bladder cancer patients who underwent staging <sup>18</sup>F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUV<sub>max</sub>) of primary tumors, total numbers, sizes, and SUV<sub>max</sub> of <sup>18</sup>F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUV<sub>max</sub> of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.</p><p><strong>Results: </strong>Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had <sup>18</sup>F-FDG positive pelvic LNs, while 24 (43.7%) patients had <sup>18</sup>F-FDG positive extra-pelvic disease. Patients with <sup>18</sup>F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of <sup>18</sup>F-FDG-positive pelvic LNs (p<0.001) and <sup>18</sup>F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The <sup>18</sup>F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.</p><p><strong>Conclusion: </strong>The presence of <sup>18</sup>F-FDG-positive extra-pelvic disease in pretreatment <sup>18</sup>F-FDG PET/CT is an important prognostic factor in bladder cancer patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899737/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Added-value of Staging <sup>18</sup>F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.\",\"authors\":\"Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak\",\"doi\":\"10.4274/mirt.galenos.2023.65002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This retrospective study aimed to evaluate the prognostic importance of <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging <sup>18</sup>F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.</p><p><strong>Methods: </strong>Bladder cancer patients who underwent staging <sup>18</sup>F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUV<sub>max</sub>) of primary tumors, total numbers, sizes, and SUV<sub>max</sub> of <sup>18</sup>F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUV<sub>max</sub> of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.</p><p><strong>Results: </strong>Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had <sup>18</sup>F-FDG positive pelvic LNs, while 24 (43.7%) patients had <sup>18</sup>F-FDG positive extra-pelvic disease. Patients with <sup>18</sup>F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of <sup>18</sup>F-FDG-positive pelvic LNs (p<0.001) and <sup>18</sup>F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The <sup>18</sup>F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.</p><p><strong>Conclusion: </strong>The presence of <sup>18</sup>F-FDG-positive extra-pelvic disease in pretreatment <sup>18</sup>F-FDG PET/CT is an important prognostic factor in bladder cancer patients.</p>\",\"PeriodicalId\":44681,\"journal\":{\"name\":\"Molecular Imaging and Radionuclide Therapy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-02-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10899737/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular Imaging and Radionuclide Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/mirt.galenos.2023.65002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2023.65002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
The Added-value of Staging 18F-FDG PET/CT in the Prediction of Overall Survival in the Patients with Bladder Cancer.
Objectives: This retrospective study aimed to evaluate the prognostic importance of 18F-fluorodeoxyglucose (18F-FDG)-positive pelvic lymph nodes (LNs) and extra-pelvic disease on staging 18F-FDG positron emission tomography/computed tomography (PET/CT) in patients with bladder cancer.
Methods: Bladder cancer patients who underwent staging 18F-FDG PET/CT were included in the study. Histopathologic features of tumors, therapy histories, presence of distinguishable tumors on CT and PET images, sizes and maximum standardized uptake value (SUVmax) of primary tumors, total numbers, sizes, and SUVmax of 18F-FDG-positive pelvic and extra-pelvic LNs, and total numbers and SUVmax of distant metastases (M1a/1b) were recorded. Patients were followed up until death or the last medical visit. Factors predicting overall survival were determined using Cox regression analysis.
Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had 18F-FDG positive pelvic LNs, while 24 (43.7%) patients had 18F-FDG positive extra-pelvic disease. Patients with 18F-FDGpositive pelvic LNs had a higher rate of extra-pelvic disease (p=0.003). The median follow-up duration was 13.5 months. The median overall survival was 16.3 months [95% confidence interval (CI) 8.9-23.7]. The primary tumor distinguishability on PET (p=0.011) and CT (p=0.009) images, the presence of 18F-FDG-positive pelvic LNs (p<0.001) and 18F-FDG-positive extra-pelvic disease/distant metastases (M1a/M1b) (p<0.001), and the number of distant metastases (p=0.034) were associated with mortality. The 18F-FDG-positive extra-pelvic disease/distant metastases [p=0.029, odds ratio: 4.15 (95% CI 1.16-14.86)] was found to be an independent predictor of mortality in patients with bladder cancer.
Conclusion: The presence of 18F-FDG-positive extra-pelvic disease in pretreatment 18F-FDG PET/CT is an important prognostic factor in bladder cancer patients.
期刊介绍：
Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
